Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer

Figure 4

Plasma pharmacokinetics of paclitaxel. The pharmacokinetics generally were linear for 6 or 24 hour infusions but become nonlinear for infusions of shorter durations due to variation in the elimination clearance with the dose administered. An increase in plasma concentration of paclitaxel, results in disproportionate larger increase in (maximum plasma concentration) and AUC (area under plasma concentration), followed by decrease in drug elimination from body tissues.